access intranet after hours circle-arrow apply blog caret circle arrow close closer look community outreach community outreach contact contact us down arrow facebook lock solid find a provider find a clinical trial find a provider find a researcher find faculty find-a-service how to apply join leadership left arrow locations logo make a gift map location maximize minimize my chart my chart notification hp notification lp next chevron right nxt prev pay your bill play previous quality and safety refer a patient request a speaker request appointment request an appointment residents corner rss search search jobs Asset 65 submit a story idea symptom checker Arrow Circle Up twitter youtube Dino Logo External Link University Logo Color University Logo Solid Health Logo Solid Arrow Right Circle Book Calendar Date Calendar Search Date Diploma Certificate Dollar Circle Donate Envelope Graduation Cap Map Pin Map Search Phone Pills Podcast


Clinical research is critical to the advancement of perinatal mental health treatment. Our program has several ongoing clinical research studies aimed at improving treatments for perinatal mood, pain, and opioid use. Below are brief descriptions of ongoing studies and opportunities to participate in clinical research.

Accelerated Theta Burst Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Postpartum Depression

This study is for those that are currently experiencing postpartum depression. The goal of the study is to see if postpartum women are willing to take part in an accelerated course of rTMS (e.g., 18 treatments over 3 days).

You may be eligible to join if you:

  • Are female aged 18 or above
  • Are experiencing depression during pregnancy or following the birth of a child

For more information and to see if you qualify please contact Edie Douglas at 843-792-0403 or

A Novel Approach to Reduce Pain, Prescription Opioid Use, & Misuse in Pregnancy

This study is for those that are pregnant and using prescription opioid medications. The goal of the study is to determine if Cognitive Behavioral Therapy for Chronic Pain and medication management can help improve functioning and reduce pain and prescription opioid medication use.

You may be eligible to join if you:

  • Are pregnant
  • Are taking prescription opioid medication

For more information and to see if you qualify please contact Edie Douglas at 843-792-0403 or

Postpartum Depression ACT

PPD ACT is a research app for women who have ever experienced postpartum depression (PPD) or psychosis (PPP). The goal of the study is to improve detection, treatment and prevention of PPD and PPP by finding the genetic basis of these disorders. Women who participate will download the PPD ACT app, fill out questionnaires and if eligible, submit a saliva sample.

You may be eligible to join if you:

  • Are female aged 18 or above
  • Have had a live birth
  • Have an iOS or Android device

For more information, find us on the web at PPD ACT, or find the app in the iTunes or Google Play store by searching “PPD ACT.”

Women’s Health Clinical Care

All patients coming to the Women’s Reproductive Behavioral Health Program for clinical care are asked to complete standardized rating scales via REDCap, a secure web-based data capturing application. This information is used for clinical care including monitoring response to treatment. The clinical information collected may be de-identified (meaning it cannot be linked to the person who completed the questionnaire) and used to inform clinical research that ultimately will improve the mental health care of pregnant and postpartum women.

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, & Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects with Severe Postpartum Depression & Adult Female Subjects with Moderate Postpartum Depression

This is a research study evaluating an investigational medication (SAGE-547, allopregnanolone) in women with moderate to severe postpartum depression. The specific purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of SAGE-547 as a treatment for women with severe or moderate postpartum depression (PPD), an area of high unmet medical need. The study consists of an up to 7-day Screening Period, 3-day inpatient Treatment Period, and 30-day Follow-up Period. Assessments and laboratory samples are collected during the Treatment Period and the Follow-up Period.

*While we are no longer enrolling participants in this study, we hope this medication will be a treatment option for women with postpartum depression in the near future.